Want to see PRPO full AI Analyst Report?
Top Page
Precipio
(NASDAQ:PRPO)
Select Model
Select Model
Rating:63Neutral
Price Target:
$32.00
▲(39.62% Upside)
Action:Reiterated
Date:08/18/26
The score is driven primarily by improving financial performance (notably the swing to positive operating and free cash flow) and a positive earnings update highlighting record revenue, accelerating product sales, and improved EBITDA/cash generation. These positives are tempered by continued GAAP profitability pressure, a mixed technical backdrop, and limited valuation support given the negative P/E and no dividend yield.
Positive Factors
Strong Revenue Growth
Rapid TTM growth and record Q2 revenue indicate expanding demand for Precipio’s cancer diagnostics. Sustained volume gains can improve laboratory utilization and operating leverage if the company maintains reimbursement and customer adoption.
Negative Factors
Persistent GAAP Losses
Despite better revenue and cash flow, Precipio has not achieved consistent GAAP profitability. Continued losses may constrain reinvestment, weaken returns on capital and make future performance dependent on maintaining favorable working-capital trends.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Rapid TTM growth and record Q2 revenue indicate expanding demand for Precipio’s cancer diagnostics. Sustained volume gains can improve laboratory utilization and operating leverage if the company maintains reimbursement and customer adoption.
Read all positive factors
Precipio (PRPO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$54.51M
Dividend YieldN/A
Average Volume (3M)19.92K
Price to Earnings (P/E)―
Beta (1Y)0.59
Revenue Growth28.04%
EPS Growth43.26%
CountryUS
Employees61
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.65
Shares Outstanding1,790,188
10 Day Avg. Volume16,445
30 Day Avg. Volume19,918
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)2.53
Price to Sales (P/S)1.53
P/FCF Ratio102.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.4
Revenue Forecast (FY)$80.26M
Precipio Business Overview & Revenue Model
Company Description
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood...
How the Company Makes Money
Precipio primarily makes money by providing diagnostic testing services performed in its laboratories and billing for those services. Revenue is generated when healthcare providers order Precipio’s tests and the company (a) performs the laboratory...
Precipio Earnings Call Summary
Earnings Call Date:Aug 14, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call presented multiple meaningful operational and financial improvements: record quarterly revenue (> $7M), strong product revenue acceleration (+35% sequential, +21% vs prior record), positive adjusted EBITDA (~$400K) and $700K operating cash generation leading to a >$3M cash balance. These positives are tempered by modest pathology sequential growth, prior distributor complexity that slowed past ramping, quarter-to-quarter timing/seasonality effects, noted execution risk to convert the expanded pipeline, and an unexplained spike in share trading. On balance, the company emphasized organic improvement and execution plans to sustain growth.Positive Updates
Record Quarterly Revenue
Q2 revenue exceeded $7.0M for the first time in company history (Q2: >$7.0M vs Q1: ~$6.7M), representing approximately a 22% year-over-year increase from $5.7M in Q2 2025.
Negative Updates
Modest Pathology Revenue Growth
Pathology revenue rose only modestly to approximately $6.1M from $6.0M in Q1, reflecting limited sequential growth as resources were shifted to accelerate product commercialization.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Quarterly Revenue
Q2 revenue exceeded $7.0M for the first time in company history (Q2: >$7.0M vs Q1: ~$6.7M), representing approximately a 22% year-over-year increase from $5.7M in Q2 2025.
Read all positive updates
Company Guidance
Guidance for the second half of 2026 centers on continued revenue growth from the Q2 momentum (Q2 topline >$7.0M, up ~22% YoY from $5.7M and up from ~$6.7M in Q1), with particular emphasis on accelerating product revenue (Q2 products ~$900K, +35% QoQ and ~21% above the prior ~$750K record) by converting the expanded commercial pipeline (added ~10 distributor reps, >25 new qualified customers, and >30 meetings in Q2) into active accounts; management expects this to drive operating leverage—building on the Q2 adjusted EBITDA of ~$400K (vs -$200K in Q1, a ~$600K swing driven by ~$300K revenue increase and ~$200K lower stock‑based comp)—and continued cash generation (operating cash flow ~$700K in Q2, ~10% of topline), with cash on hand >$3M (up ~$0.5M this quarter vs ~$1.1M a year ago) without raising capital.Precipio Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
67
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.46M | 24.05M | 15.96M | 15.20M | 9.41M | 8.85M |
| Gross Profit | 12.00M | 10.71M | 7.56M | 6.02M | 2.51M | 2.39M |
| EBITDA | 246.00K | 1.46M | -2.70M | -4.53M | -10.65M | -7.05M |
| Net Income | -1.22M | -363.00K | -4.29M | -5.85M | -12.20M | -8.55M |
Balance Sheet | ||||||
| Total Assets | 21.32M | 21.32M | 17.00M | 18.10M | 21.50M | 30.44M |
| Cash, Cash Equivalents and Short-Term Investments | 3.08M | 6.04M | 1.39M | 1.50M | 3.44M | 11.67M |
| Total Debt | 3.34M | 3.65M | 1.25M | 1.12M | 1.39M | 1.43M |
| Total Liabilities | 6.56M | 6.76M | 4.90M | 3.67M | 5.14M | 5.83M |
| Stockholders Equity | 14.76M | 14.56M | 12.09M | 14.43M | 16.30M | 24.56M |
Cash Flow | ||||||
| Free Cash Flow | 789.00K | 359.00K | 216.00K | -3.69M | -8.00M | -7.26M |
| Operating Cash Flow | 1.10M | 685.00K | 439.00K | -3.56M | -7.72M | -6.58M |
| Investing Cash Flow | -311.00K | -326.00K | -223.00K | -126.00K | -277.00K | -682.00K |
| Financing Cash Flow | 1.16M | 903.00K | -329.00K | 1.74M | -225.00K | 16.27M |
Precipio Technical Analysis
Positive
22.92
Price Trends
23.81
Positive
25.32
Positive
24.69
Positive
Market Momentum
1.16
Negative
76.84
Negative
99.30
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRPO, the sentiment is Positive. The current price of 22.92 is below the 20-day moving average (MA) of 23.83, below the 50-day MA of 23.81, and below the 200-day MA of 24.69, indicating a bullish trend. The MACD of 1.16 indicates Negative momentum. The RSI at 76.84 is Negative, neither overbought nor oversold. The STOCH value of 99.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRPO.
Precipio Risk Analysis
Precipio disclosed 62 risk factors in its most recent earnings report. Precipio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Precipio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $54.51M | -46.85 | -8.49% | ― | 28.04% | 43.26% | |
60 Neutral | $2.18B | -8.56 | -6.31% | ― | 11.19% | 50.58% | |
60 Neutral | $22.91B | -48.91 | 211.46% | ― | 42.74% | -4.60% | |
59 Neutral | $47.86B | -244.14 | -11.73% | ― | 37.82% | 28.02% | |
59 Neutral | $280.98M | -8.40 | -788.19% | ― | 34.46% | 43.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $306.08M | -2.68 | -32.59% | ― | -3.16% | 72.02% |
* Healthcare Sector Average
PRPO
Precipio
30.45
16.26
114.59%
MYGN
Myriad Genetics
3.20
-2.69
-45.67%
NEO
NeoGenomics
16.98
10.53
163.26%
NTRA
Natera
332.03
169.56
104.36%
GH
Guardant Health
170.69
108.81
175.84%
BDSX
Biodesix
26.63
16.84
172.01%
Precipio Corporate Events
Business Operations and StrategyFinancial Disclosures
Precipio Schedules Q2 2026 Shareholder Update Call
Positive
Jul 31, 2026
On July 31, 2026, New Haven-based Precipio, Inc. announced it would host its Q2 2026 shareholder update call on August 17, 2026, at 5:00 p.m. ET to discuss performance across its core cancer diagnostics businesses. The call will feature prepared r...
Executive/Board ChangesShareholder Meetings
Precipio Shareholders Back Board Nominees and Auditor
Positive
Jun 15, 2026
On June 15, 2026, Precipio, Inc. held its Annual Meeting of stockholders, with 1,063,293 shares present or represented by proxy, accounting for 59.57% of the company’s outstanding common stock entitled to vote. Stockholders elected Richard S...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.